Trial · NCT07910357
High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in Children High-altitude Pulmonary Edema
NCT07910357, Not applicable, Not yet recruiting, Ye Fan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in Children High-altitude Pulmonary Edema. Trials, record NCT07910357. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910357
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in Children High-altitude Pulmonary Edema
- NCT number
- NCT07910357
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 116 participants, estimated
- Lead sponsor
- Ye Fan
- Conditions
- High-altitude Pulmonary Edema
- Interventions
- High-flow Nasal Cannula Oxygen Therapy (HFNC)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of treatment failure | From date of randomization until the time of first documented treatment failure from any cause, or until hospital discharge, assessed up to 5 days | Treatment failure: defined as the proportion of children who still cannot maintain target oxygen saturation or present with severe respiratory distress after standardized optimization of current oxygen-therapy parameters to the maximum recommended intensity, requiring escalation to non-invasive positive-pressure ventilation or invasive mechanical ventilation, or manifesting significant intolerance to the assigned oxygen therapy. |
| Secondary | Time to weaning off supplemental oxygen | From date of randomization to oxygen therapy completion (oxygen weaning),an average of 3-5 days | Hours from randomization to successful weaning to room air |
| Secondary | Net change in imaging Pulmonary Edema Score | Day 3 post-randomization | Change in imaging Pulmonary Edema Score from baseline to Day 3 post-randomization |
| Secondary | Evolvement of SpO2 | From enrollment to treatment completion, an average of 3-5 days | SpO2 is the percentage of oxygen-saturated hemoglobin in the blood, indicating how well oxygen is being delivered throughout the body. It was measured non-invasively using a pulse oximeter, a small device placed on a participant's fingertip, which uses light to estimate blood oxygen levels. |
| Secondary | Incidence of oxygen therapy-related complications | From randomization to discharge, assessed up to about 5 days | Incidence of oxygen therapy-related complications during hospital stay |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910357
GET https://conductscience.org/api/trials/v1/NCT07910357/registered